首站-论文投稿智能助手
典型文献
Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients
文献摘要:
Background::The impact of sex on the clinical manifestations of rheumatoid arthritis (RA) were diversely reported in the literature. The Chinese Registry of rhEumatoiD arthrITis provides a platform for the investigation of this issue in Chinese patients.Methods::Demographic and clinical parameters were collected from all enrolled patients with RA and from patients with early RA (disease duration ≤6 months). The differences in data regarding disease activity, comorbidities, and medications for RA were compared between men and women. The proportions of patients who achieved remission and low disease activity were compared at enrollment and during 3-, 6-, and 12-month follow-up visits.Results::A total of 11,564 patients were enrolled, 83.6% of whom were female. In all the enrolled patients and patients with early RA, C-reactive protein (CRP, 12.0 vs. 6.7 mg/L), pain visual analogue scale (4.8 vs. 4.5), patient’s and physician’s global assessment (4.9 vs. 4.5 and 4.9 vs. 4.5), 28-joint disease activity score using DAS28-CRP (4.3 vs. 4.0) simplified disease activity index (21.9 vs. 19.9), and clinical disease activity index (19.3 vs. 18.0) were significantly higher in men than in women. Additionally, the swollen joint count/tender joint count and DAS28 using erythrocyte sedimentation rate were higher in male patients than in female patients with early RA. More female patients with early RA reached the treatment target at baseline than male patients (23.4% vs. 18.2%, assessed by CDAI). At 3 months, 6 months, and 12 months, the proportion of remission and treatment target achievement was similar in both sexes. Coronary artery disease (CAD) and stroke were more frequent in men than in women. Conclusions::In Chinese patients with RA, men were found to have more active disease, as well as more cases of CAD and stroke. Therefore, sex should be carefully considered during the personalization of RA treatment.
文献关键词:
Rheumatoid arthritis;Sex;Disease activity;Treatment target;Comorbidities
作者姓名:
Jiang Nan;Li Qin;Li Hongbin;Fang Yongfei;Wu Lijun;Duan Xinwang;Xu Jian;Zhao Cheng;Jiang Zhenyu;Wang Yanhong;Wang Qian;Leng Xiaomei;Li Mengtao;Tian Xinping;Zeng Xiaofeng;CREDIT Co-Authors
作者机构:
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science and Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China;Department of Rheumatology, the First People’s Hospital of Yunnan Province, Kunming, Yunnan 650032, China;Department of Rheumatology, the Affiliated Hospital of Inner Mongolia Medical College, Hohhot, Inner Mongolia 010050, China;Department of Rheumatology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China;Department of Rheumatology and Immunology, People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830001, China;Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China;Department of Rheumatology and Immunology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China;Department of Rheumatology, The First Affiliated Hospital of Guangxi Medical University, Manning, Guangxi 530021, China;Department of Rheumatology, The First Hospital of Jilin University, Changchun, Jilin 130021, China;Department of Epidemiology and Bio-Statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100005, China
引用格式:
[1]Jiang Nan;Li Qin;Li Hongbin;Fang Yongfei;Wu Lijun;Duan Xinwang;Xu Jian;Zhao Cheng;Jiang Zhenyu;Wang Yanhong;Wang Qian;Leng Xiaomei;Li Mengtao;Tian Xinping;Zeng Xiaofeng;CREDIT Co-Authors-.Chinese registry of rheumatoid arthritis (CREDIT) V: sex impacts rheumatoid arthritis in Chinese patients)[J].中华医学杂志(英文版),2022(18):2210-2217
A类:
CREDIT,diversely,rhEumatoiD,arthrITis
B类:
Chinese,registry,rheumatoid,arthritis,impacts,patients,Background,clinical,manifestations,RA,were,reported,literature,Registry,provides,platform,investigation,this,issue,Methods,Demographic,parameters,collected,from,enrolled,early,disease,duration,months,differences,data,regarding,activity,comorbidities,medications,compared,between,women,proportions,achieved,remission,enrollment,during,follow,up,visits,Results,total,whom,female,In,reactive,protein,pain,visual,analogue,scale,physician,global,assessment,joint,score,using,DAS28,simplified,significantly,higher,than,Additionally,swollen,count,tender,erythrocyte,sedimentation,rate,More,reached,treatment,target,baseline,assessed,by,CDAI,At,achievement,was,similar,both,sexes,Coronary,artery,CAD,stroke,more,frequent,Conclusions,found,have,well,cases,Therefore,should,carefully,considered,personalization,Rheumatoid,Sex,Disease,Treatment,Comorbidities
AB值:
0.449302
相似文献
Meso-Rex bypass for the management of extrahepatic portal vein obstruction in adults (with video)
Martin Brichard;Samuele Iesari;Jan Lerut;Raymond Reding;Pierre Goffette;Laurent Coubeau-Service de Chirurgie et Transplantation Abdominale,Cliniques Universitaires Saint-Luc,Université Catholique de Louvain,10 Avenue Hippocrate,Brussels 1200,Belgium;P?le de Chirurgie Expérimentale et Transplantation,Institut de Recherche Expérimentale et Clinique,UniversitéCatholique de Louvain,Brussels,Belgium;Department of Clinical Sciences and Applied Biotechnology,University of L'Aquila,L'Aquila,Italy;Department of General Surgery and Kidney Transplantation,Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico,Milan,Italy;Service de Radiologie et Imagerie médicale,Cliniques Universitaires Saint-Luc,Université Catholique de Louvain,Brussels,Belgium
Knowledge about,attitude and acceptance towards,and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China:A cross-sectional survey
Jing Hong;Xiao-wan Xu;Jing Yang;Jing Zheng;Shu-mei Dai;Ju Zhou;Qing-mei Zhang;Yi Ruan;Chang-quan Ling-School of Traditional Chinese Medicine,Naval Medical University,Shanghai 200433,China;Department of Integrative Oncology,Changhai Hospital,Naval Medical University,Shanghai 200433,China;Department of Oncology,The First Affiliated Hospital,Bengbu Medical College,Bengbu 233010,Anhui Province,China;Department of Nursing,Fuyang Cancer Hospital,Fuyang 236000,Anhui Province,China;Department of Cardiac Rehabilitation,Shanghai First Rehabilitation Hospital,Shanghai 200090,China;Department of Radiation Oncology,Anhui Chest Hospital,Hefei 230022,Anhui Province,China;Department of Anesthesiology,Chaohu Hospital,Anhui Medical University,Hefei 238000,Anhui Province,China
Post-discharge mortality in the first wave of COVID-19 in Turkey
Fusun Fakili;Pelin Duru Cetinkaya;Oya Baydar;Serap Argun Baris;Nurdan Kokturk;Seval Kul;Oguz Karcioglu;Pinar Aysert Yildiz;Ilim Irmak;Yonca Sekibag;Emel Azak;Sait Mulamahmutoglu;Caglar Cuhadaroglu;Bugra Kerget;Burcu Baran Ketencioglu;Hasan Selcuk Ozger;Gulcihan Ozkan;Zeynep Ture;Merve Ercelik;Tansu Ulukavak Ciftci;Ozlem Alici;Esra Nurlu Temel;Ozlem Ataoglu;Neslihan Kose;Muge Meltem Tor;Gulsah Gunluoglu;Sedat Altin;Onder Ozturk;Pinar Yildiz Gulhan;Ilknur Basyigit;Hasim Boyaci;I.Kivilcim Oguzulgen;Sermin Borekci;Bilun Gemicioglu;Ismail Hanta;Hacer Kuzu Okur;Gulseren Sagcan;Metin Akgun;Ali Fuat Kalyoncu;Oya Itil;Hasan Bayram-Department of Pulmonary Medicine,Faculty of Medicine,Gaziantep University,Gaziantep,Turkey;Department of Pulmonary Medicine,University of Health Sciences,Adana City Training and Research Hospital,Adana,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Cukurova University,Adana,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Kocaeli University,Kocaeli,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Gazi University,Ankara,Turkey;Department of Biostatistics,Faculty of Medicine,Gaziantep University,Gaziantep,Turkey;Department of Pulmonary Medicine,Halil Sivgin Cubuk State Hospital,Ankara,Turkey;Department of Infectious Disease,Faculty of Medicine,Gazi University,Ankara,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Hacettepe University,Ankara,Turkey;Department of Pulmonary Medicine,Cerrahpasa Faculty of Medicine,Istanbul University-Cerrahpasa,Istanbul,Turkey;Department of Infectious Disease and Clinical Microbiology,Faculty of Medicine,Kocaeli University,Kocaeli Turkey;Department of Pulmonary Medicine,Altunizade Acibadem Hospital,Istanbul,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Ataturk University,Erzurum,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Erciyes University,Kayseri,Turkey;Department of Pulmonary Medicine,Maslak Acibadem Hospital,Istanbul,Turkey;Department of Infectious Disease and Clinical Microbiology,Faculty of Medicine,Erciyes University,Kayseri,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Duzce University,Duzce,Turkey;Department of Infectious Disease,Faculty of Medicine,Turkiye Gazetesi Private Hospital,Istanbul,Turkey;Department of Infectious Diseases and Clinical Microbiology,Faculty of Medicine,Suleyman Demirel University,Isparta,Turkey;Department of Pulmonary Medicine,Bilecik Training and Research Hospital,Bilecik,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Zonguldak Bulent Ecevit University,Zonguldak,Turkey;Department of Pulmonary Medicine,University of Health Science,Yedikule Chest Diseases and Chest Surgery Training and Research Hospital,Istanbul,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Suleyman Demirel University,Isparta,Turkey;Department of Pulmonary Medicine,Faculty of Medicine,Dokuz Eylul University,Izmir,Turkey;Department of Pulmonary Medicine,Koc University Research Center for Translational Medicine(KUTTAM),Koc University School of Medicine,Istanbul,Turkey
Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail
Chen Nan;Xing Changying;Niu Jianying;Liu Bicheng;Fu Junzhou;Zhao Jiuyang;Ni Zhaohui;Wang Mei;Liu Wenhu;Zhao Jinghong;Zhong Ling;Wu Xiongfei;Li Wenge;Chen Yuqing;Shi Wei;Chen Jianghua;Yin Aiping;Fu Ping;Wang Rong;Jiang Gengru;Hou Fanfan;Ding Guohua;Chen Jing;Xu Gang;Kondo Yuichiro;Su Yuliang;Mei Changlin-Department of Nephrology, Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200025, China;Department of Nephrology, Jiangsu Provincial Hospital, Nanjing, Jiangsu 210036, China;Department of Nephrology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China;Department of Nephrology, Zhongda Hospital Southeast University, Nanjing, Jiangsu 210009, China;Department of Nephrology, Guangzhou First People's Hospital, Guangzhou, Guangdong 510180, China;Department of Nephrology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116027, China;Department of Nephrology, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai 200001, China;Department of Nephrology, Peking University People's Hospital, Beijing 100044, China;Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;Department of Nephrology, Xinqiao Hospital of Army Medical University, Chongqing 400037, China;Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China;Department of Nephrology, Southwest Hospital of Army Medical University, Chongqing 400039, China;Department of Nephrology, China-Japan Friendship Hospital, Beijing 100029, China;Department of Nephrology, Peking University First Hospital, Beijing 100034, China;Department of Nephrology, Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080, China;Department of Nephrology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China;Department of Nephrology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China;Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China;Department of Nephrology, Shandong Provincial Hospital, Jinan, Shandong 250021, China;Department of Nephrology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China;Department of Nephrology, Nanfang Hospital Southern Medical University, Guangzhou, Guangdong 510510, China;Department of Nephrology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China;Department of Nephrology, Huashan Hospital, Fudan University, Shanghai 200040, China;Department of Nephrology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 430030, China;R&D Planning Department, R&D Division, Kyowa Kirin Co., Ltd, Tokyo 520-5292, Japan;D&R office, Kyowa Kirin China Pharmaceutical Co., Ltd, Shanghai 201203, China;Department of Nephrology, Shanghai Changzheng Hospital, Shanghai 200003, China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。